Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Steward

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 3, 2006
Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trialsR G Tunstall, R A Sharma, S Perkins, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancerD I Jodrell, W Oster, D J Kerr, et al.
Seminars in Oncology|September 5, 1998
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug deliveryR P Abratt, A Sandler, L Crinò, et al.
British Journal of Cancer|August 19, 2004
Growth-inhibitory and cell cycle-arresting properties of the rice bran constituent tricin in human-derived breast cancer cells in vitro and in nude mice in vivoH Cai, E A Hudson, P Mann, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1984
A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphomaW P Steward, I D Todd, M Harris, et al.
Clinical Nutrition (Edinburgh, Scotland)|October 22, 2013
Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancerA Arshad, W Y Chung, J Isherwood, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2007
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I studyW P Steward, M Middleton, A Benghiat, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2008
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastasesC P Neal, C D Mann, C D Sutton, et al.
Seminars in Oncology|February 1, 1992
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma GroupG Blackledge, W P Steward, J Verweij, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 18, 2011
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamicsLynne M Howells, D P Berry, P J Elliott, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|January 3, 2006
Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trialsR G Tunstall, R A Sharma, S Perkins, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancerD I Jodrell, W Oster, D J Kerr, et al.
Seminars in Oncology|September 5, 1998
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug deliveryR P Abratt, A Sandler, L Crinò, et al.
British Journal of Cancer|August 19, 2004
Growth-inhibitory and cell cycle-arresting properties of the rice bran constituent tricin in human-derived breast cancer cells in vitro and in nude mice in vivoH Cai, E A Hudson, P Mann, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1984
A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphomaW P Steward, I D Todd, M Harris, et al.
Clinical Nutrition (Edinburgh, Scotland)|October 22, 2013
Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancerA Arshad, W Y Chung, J Isherwood, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2007
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I studyW P Steward, M Middleton, A Benghiat, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2008
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastasesC P Neal, C D Mann, C D Sutton, et al.
Seminars in Oncology|February 1, 1992
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma GroupG Blackledge, W P Steward, J Verweij, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 18, 2011
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamicsLynne M Howells, D P Berry, P J Elliott, et al.
Pageof 13